EC Ophthalmology

Treatment and management of proliferative vitreo-retinopathy (PVR) is a much difficult and actual problem in ophthalmology. In recent times newer tendencies of using antiproliferative agents in various carriers.

PVR is a typical intraocular pathology characterized by localized scar formations, liquidation and alterations in the structure of vitreous body. It occurs mainly due to retinal detachment, vitreous hemorrhage, trauma and diabetic retinopathy [1].

PVR constitutes 2-9% of total ocular pathology and 84-89% of individuals suffering from this condition are from the working age group. This highlights the social significance of this problem [2-4].

Treatment of PVR requires complex surgical treatment which constitutes multiple stages [5]. In absence such complex surgical treatment blindness occurs in 100% cases [6-8].

In the recent years, with the significant advances in the modern surgical treatment methods in treatment of retinal detachment both intra operative and post operative complications have reduced and success rate of achieving morphological and functional results have increased manifolds. However despite such advances in diagnostic tools and in surgical methods of treatment, the success rate varies between 61.5 – 97.5% [9-13].

Progression of PVR in post operative period is one of the main reasons of failed retinal detachment surgery and is observed in 2.2-29.4% of cases [9,11,13,14]. Secondary retinal detachment due to progressive PVR constitutes 2.2 to 20.0% [11,13,15-17].

Modern surgical methods of PVR has employed various antiproliferative agents doped on carriers or implants during the primary surgery itself. Widely used are agents which inhibit the scar formation namely cytostatic agents. 5 FLUOROURACIL (5FU) is the most popular agent [18].

In the recent years there has been significant interest in agents based on chitin and chitosan. These agents are highly biocompatible and get assimilated in the organism. They also exhibit anti-inflammatory action, are biocompatible and improve regeneration of cells and tissues [19-21].

Jurgumbaev G.K. jointly with institute of Chemical sciences, department of polymer synthesis named after Bekturova A. B. developed vitreosyneretic <VITRENAL> a water soluble polymer of chitosan. Clinical experiments conducted have shown effectiveness of intra vitreal injection of water soluble vitrenal in surgical treatment of PVR in retinal detachment and ocular trauma.

The main objective of this study is effectiveness of chitosan film saturated with 5FU on the ocular structures in experimental conditions.

Keywords: Proliferative Vitreo-Retinopathy; Antiproliferative Agents; Retinal Detachment

1. Sosnovski SV., et al. “Devising a system of justification of gravity of proliferative vitreoretinopathy”. Surgical Ophthalmology 4 (2009): 25.
2. Zakharov VD and Balynskaya NP. “Combined intravitreal surgical intervention in retinal detachment complicated by vitreo retinal traction”. Surgical Ophthalmology 1 (1997): 28-34.
3. Ilyitskii VV. “Temporary and permanent episcleral buckling in surgery of retinal detachment and its prophylaxis (postdoctoral dissertation)”. Moscow (1994): 40.
4. Kochmala OB., et al. “Surgery of retinal detachment: Modern day problems”. Vest Ophthalmology 6 (2010): 46-49.
5. Zakharov VD. “Vitreoretinal surgery”. M. Medicina (2003): 180.
6. Glinchuk YaI. “Role of vitrectomy in treatment of ocular disease of traumatic degenerative and inflammatory etiology (doctoral dissertation)”. Moscow (1987): 378.
7. Jurgumbaeva GK. “Vitreosyneretic <Vitrenal> in surgery of proliferative vitreoretinopathy in retinal detachment (doctoral dissertation)”. Almaty (2009): 112.
8. Zakharov VD., et al. “Possibilities of treatment of proliferative vitreoretinopathy in light of modern aspects of its etiology and pathogenesis”. Surgical Ophthalmology 2 (2006): 59-65.
9. Afrashi F., et al. “Conventional buckling surgery or primary vitrectomy with silicone oil tamponade in rhegmatogenous retinal detachment with multiple breaks”. Graefe's Archive for Clinical and Experimental Ophthalmology4 (2004): 295-300.
10. Christensen U and Villumsen J. “Prognosis of pseudophakic retinal detachment”. Journal of Cataract and Refractive Surgery2 (2005): 354-358.
11. Goezinne F., et al. “Incidence of redetach¬ment 6 months after scleral buckling surgery”. Acta Ophthalmology2 (2010): 199-206.
12. Heimann H., et al. “Primary vitrectomy for rhegmatog¬enous retinal de¬tachment: an analysis of 512 cases”. Graefe's Archive for Clinical and Experimental Ophthalmology1 (2006): 69-78.
13. Salicone A., et al. “Management of reti¬nal detach¬ment when no break is found”. Ophthalmology3 (2006): 398-403.
14. Kon CH., et al. “Risk factors for proliferative vit¬reoretinopathy after primary vitrectomy: a prospective study”. British Journal of Ophthalmology5 (2000): 506-511.
15. Foster RE and Meyers SM. “Recurrent retinal detachment more than 1 year af¬ter reattach¬ment”. Ophthalmology10 (2002): 1821-1827.
16. Miki D., et al. “Comparison of scleral buckling and vitrec¬tomy for reti¬nal detachment resulting from flap tears in superior quadrants”. The Japanese Journal of Ophthalmology2 (2001): 187-191.
17. Sharma YR., et al. “Functional and anatomic out¬come of scle¬ral buckling versus primary vitrectomy in pseudophakic retinal detachment”. Acta Ophthalmologica Scandinavica3 (2005): 293-297.
18. Sharipova DN. “Prophylaxis of proliferative vitreoretinopathy by using 5 fluorouracil on hydrogel implants(doctoral dissertation )”. Moscow (2006): 109.
19. Kuzhovnikov VV., et al. “Use of medical grade items based on chitosan in ophthalmology”. Materials used from international conference: modern perspectives of using chitin and chitosan., Stavrapol (2008): 181-183.
20. Lazarenko VI., et al. “Experience in usage of medical grade items <BOL-Chit> and <Kollachit-bol> in ophthalmology”. Russian Ophthalmology Journal4 (2009): 21-24.
21. Yang H., et al. “Feasibility study of chitosan as intravitreous tamponade mate¬rial”. Graefe's Archive for Clinical and Experimental Ophthalmology 246 (2008): 1095-1097.
22. Aksenov AO. “Surgical treatment of patients of retinal detachment using extrascleral buckling procedure with silicon sponges: doctoral dissertation”. -M (1985).
23. Antelava NB. “Clinical study and treatment of proliferative vitreoretinopathy in rhegmatogenous retinal detachment: doctoral dissertation”. -M (1998).
24. Belyaev VC. “Manual of ocular surgery. – M (1988): 84-183.
25. Ryan SJ. “The pathophysiology of proliferative vitreoretinopathy in its management”. The American Journal of Ophthalmology 100 (1985): 188-193.
26. Glinchuk YaI., et al. “Results of surgical treatment of retinal detachment retinal re-detachment and complications due to severe proliferative vitreoretinopathy”. Ophthalmosurgery 2 (1994): 20-25.
27. Glinchuk YaI., et al. “Treatment of retinal detachment complicated by proliferative vitreo-retinopathy//1st congress of Russian ophthalmologists. Theses of paper presentations”. -M (1994): 132.
28. Danylichev VF. “Modern ophthalmology”. Petersburg (2000).
29. Aaberg TM. “Management of anterior and posterior proliferative vitreoretinopathy. XLV. Edward Jackson memorial lecture”. American Journal of Ophthalmology 106 (1988): 519-532.
30. Holekamp NM and Grant MG. “Vitreoctomy for the management of recur¬rent retinal detachements”. Current Opinion in Ophthalmology 8 (1997): 44-49.
31. Jalkh AE., et al. “Surgical treatments of proliferative vitreoretinopathy”. American Journal of Ophthalmology 102 (1984): 1135-1139.
32. Jalkh AE and Schepens CL. “Results of conventional vitreous surgery for proliferative vitreoretinopathy”. Archives of Ophthalmology 100 (1985): 858-859.
33. Michels RG. “Surgery of retinal detachement with proliferative vitreoretinopathy”. Retin 4 (1984): 63-83.
34. Schechter RJ. “Management of anterior and posterior proliferative vitreoretinopathy XLV Edward Jackson memorial lecture”. American Journal of Ophthalmology 107 (1989): 196.
35. Stripe M and Orciuolo M. “Vitrectomy, scleral buckling, and peripheral dia¬thermy. Treatment for severe proliferative vitreoretinopathy”. Retina 7 (1979): 219-222.
36. Jurgumbaeva GK. Vitreosyneretic <Vitrenal> in surgery for proliferative vitreoretinopathy in retinal detachment: doctoral dissertation Almaty (2009): 112.
37. Troyanovskii RL., et al. “Macular balloon: A report based on 10 years of its application in retinal detachment with macular hole and anomalies of optic nerve”. Compilation of papers presented during VII congress of Russian ophthalmologists -M (2000): 497.
38. Sdobnikova SV., et al. “Once again about tactics of surgical treatment of retinal detachment not complicated by proliferative vitreo-retinopathy”. compilation of papers presented during VIII congress of Russian ophthalmologists. -M (2005): 304-305.
39. Grigoropulos VG., et al. “Outcomesofsurgeryforprogressivesymptomaticretinaldetachmentcomplicatingretinoschisis”. Retina 26 (2006): 37-43.
40. Balinskaya NR. “Combined intravitreal manipulations during surgical treatment of retinal detachment complicated by vitreoretinal traction”. Doctoral Dissertation -M (1994): 121.
41. Logai IM and Rodin SS. “Reasons and results of unsuccessful vitrectomy in retinal detachment with multiple retinal breaks”. Journal of Ophthalmology 1 (2000): 47-50.
42. Kreissig I. “Clinical experience with SF6-gas in detachment surgery”. Berichte der Deutschen Ophthalmologischen Gesellschaft 76 (1979): 553-560.
43. Zakharov VD. Retinal detachment surgery: postdoctoral dissertation – M (1985): 390.
44. Cheema RA., et al. “Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy”. Ophthalmic Surgery, Lasers and Imaging Retina5 (2007): 365-370.
45. Cai J., et al. “Cytotoxic effects of antiproliferative agents on human retinal glial cells in vitro”. International Ophthalmology4 (2001): 225-231.
46. Capeans C., et al. “Role of inhibitors of isoprenylation in proliferation, phenotype and apoptosis of human retinal pig¬ment epithelium”. Graefe's Archive for Clinical and Experimental Ophthalmology3 (2001): 188-198.
47. Kawahara S., et al. “Potent inhibition of cicatricial con¬traction in diseases by statins”. Diabetes10 (2008): 2784-2793.
48. Turgut B., et al. “The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy”. Retina2 (2012): 232-241.
49. Van Bockxmeer F.M., et al. “Models for as¬sessing scar tissue inhibitors”. Retina1 (1985): 47-60.
50. Kuo HK., et al. “Attenuated glial reaction in experi¬mental proliferative vitreoretinopathy treated with liposomal Doxorubi¬cin”. Investigative Ophthalmology and Visual Science6 (2012): 3167-3174.